Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2016

View Archived Issues

Sun Biopharma reports progress on phase I trial of SBP-101

CASI Pharmaceuticals' phase II trial of ENMD-2076 meets stage I endpoint

Boehringer Ingelheim Pharma patents aldosterone synthase inhibitors

Anthera Pharmaceuticals says phase III SOLUTION trial will continue

Genentech and Constellation Pharmaceuticals disclose TAF1 inhibitors

Genentech and Constellation Pharmaceuticals present KDM1A inhibitors

Neurocrine Biosciences describes antiepileptic agents

Cancer Research UK launches phase I/II trial to evaluate guadecitabine in resistant bladder cancer

Janssen Research & Development gains FDA breakthrough designation for esketamine

NSAID class may be repurposed to treat Alzheimer's disease

Phase III AFFINITY trial of custirsen does not meet the primary endpoint

Vyriad signs license collaboration with Imanis Life Sciences

Xycrobe Therapeutics enters research agreement with Johnson & Johnson

Promising phase III topline results for RBP-6000 monthly depot to treat opioid use disorder

Trek Therapeutics in-licenses rights to Medivir's MIV-802

Evgen receives CTA in U.K. for phase II breast cancer trial of SFX-01

Thalidomide reduces VEGF levels in trial in patients with POEMS syndrome

Eiger initiates phase II trial of pegylated interferon lambda for chronic HDV infection

Oncoceutics Pharmaceuticals wins FDA orphan grant for phase II trial of ONC-201

Japan Tobacco seeks Japanese approval for emtricitabine/tenofovir alafenamide

Study adds to complexity of nasal flu vaccine picture

Pilot study explores use of high-dose thyroid hormone to promote remyelination in MS

Phase II trial explores use of abituzumab in systemic sclerosis-associated interstitial lung disease

Karus Therapeutics initiates phase I trial of KA-2237 in B-cell lymphoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...